論文

査読有り
2018年5月31日

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

Gastric Cancer
  • Atsuo Takashima
  • ,
  • Kohei Shitara
  • ,
  • Kazumasa Fujitani
  • ,
  • Keisuke Koeda
  • ,
  • Hiroki Hara
  • ,
  • Norisuke Nakayama
  • ,
  • Shuichi Hironaka
  • ,
  • Kazuhiro Nishikawa
  • ,
  • Yutaka Kimura
  • ,
  • Kenji Amagai
  • ,
  • Hirofumi Fujii
  • ,
  • Kei Muro
  • ,
  • Taito Esaki
  • ,
  • Yasuhiro Choda
  • ,
  • Toshimi Takano
  • ,
  • Keisho Chin
  • ,
  • Atsushi Sato
  • ,
  • Masahiro Goto
  • ,
  • Norimasa Fukushima
  • ,
  • Takuo Hara
  • ,
  • Nozomu Machida
  • ,
  • Manabu Ohta
  • ,
  • Narikazu Boku
  • ,
  • Masashi Shimura
  • ,
  • Satoshi Morita
  • ,
  • Wasaburo Koizumi

開始ページ
1
終了ページ
9
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s10120-018-0838-6
出版者・発行元
Springer Tokyo

Background: In the ABSOLUTE trial, weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) showed non-inferiority to weekly solvent-based paclitaxel (w-sb-PTX) for overall survival (OS). Thus, w-nab-PTX might be an option for second-line chemotherapy in advanced gastric cancer (AGC). However, predictive factors for efficacies of these agents have not been evaluated. Methods: Patients previously enrolled in the ABSOLUTE trial were divided into apparent peritoneal metastasis group (PM group) and no apparent peritoneal metastasis group (no PM group) based on baseline imaging evaluated by RECIST ver. 1.1 criteria and amount of ascites. OS, progression-free survival, and overall response rate were compared between two arms in each group. Results: This study included 240 and 243 patients in the w-nab-PTX and w-sb-PTX arms, respectively. In the PM group, the w-nab-PTX arm (n = 88) had longer OS than the w-sb-PTX arm (n = 103), and median survival time (MST) of 9.9 and 8.7 months [hazard ratio (HR) 0.63
95% CI 0.45–0.88
P = 0.0060], respectively. In the no PM group, the w-nab-PTX arm (n = 140) had shorter OS than the w-sb-PTX arm (n = 152), and MST of 11.6 and 15.7 months (HR 1.40
95% CI 1.06–1.86
P = 0.0180), respectively. After adjusting for prognostic factors, the HR for OS in the w-nab-PTX arm versus the w-sb-PTX arm was 0.59 (95% CI 0.42–0.83
P = 0.0023
PM group) and 1.34 (95% CI 1.01–1.78
P = 0.0414
no PM group), with significant interaction between treatment efficacy and presence of peritoneal metastasis (P = 0.0003). Conclusions: The presence of apparent peritoneal metastasis might be a predictive factor for selecting w-nab-PTX for pretreated AGC patients. Trial registration number: JapicCTI-132059.

リンク情報
DOI
https://doi.org/10.1007/s10120-018-0838-6
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29855738
ID情報
  • DOI : 10.1007/s10120-018-0838-6
  • ISSN : 1436-3305
  • ISSN : 1436-3291
  • PubMed ID : 29855738
  • SCOPUS ID : 85047960901

エクスポート
BibTeX RIS